scholarly journals Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Konstantinos Gourgoulianis ◽  
Alessandro Ruggieri ◽  
Alessandra del Vecchio ◽  
Fabrizio Calisti ◽  
Alessandro Comandini ◽  
...  
Keyword(s):  
Prospective Study ◽  
Chronic Bronchitis ◽  
Real Life ◽  
Routine Care ◽  
Symptom Improvement ◽  
Type I ◽  
Real World Evidence ◽  
Acute Exacerbations ◽  
Sputum Volume ◽  
Multicentre Prospective Study

Real-world evidence regarding the effectiveness of prulifloxacin in the treatment of acute exacerbations of chronic bronchitis (AECB) is limited. Therefore, this study aimed to assess the rates and time to symptom improvement and resolution in patients with moderate-to-severe AECB who were given prulifloxacin in the routine care in Greece. This observational, prospective study, conducted in 15 hospital-based clinics across Greece, enrolled outpatients >40 years old, with moderate-to-severe AECB, for whom the physician had decided to initiate treatment with prulifloxacin. Data were collected at prulifloxacin onset (baseline), 7–10 days after baseline, and at least 28 days after therapy completion. Between 23 November 2015 and 27 January 2018, 305 patients (males: 76.4%; mean (standard deviation) (SD) age: 69.7 (9.8) years; Anthonisen type I/II: 94.8%; chronic bronchitis duration >10 years: 24.9%) were consecutively enrolled. At baseline, >80% had increased sputum volume, cough, dyspnoea, and sputum purulence. Prulifloxacin improved symptoms in 99.7% of the patients after a mean (SD) of 5.47 (3.57) days, while symptoms fully recovered after a mean (SD) of 10.22 (5.00) days in 95.4%. The rate of adverse events related to prulifloxacin was 1.3% (serious: 0.7%). In the routine care in Greece, prulifloxacin was highly effective in moderate-to-severe AECB, while displaying a predictable safety profile.

Real-Life Treatment of Acute Exacerbations of Chronic Bronchitis with Moxifloxacin or Macrolides

2006 ◽  
Vol 26 (12) ◽  
pp. 733-744 ◽  
Author(s):  
T Schaberg ◽  
M M??ller ◽  
T File ◽  
K Stauch ◽  
H Landen
Keyword(s):  
Chronic Bronchitis ◽  
Real Life ◽  
Acute Exacerbations

Cefodizime and cefotaxime in acute exacerbations of chronic bronchitis: a randomized double-blind prospective study in 180 patients

1990 ◽  
Vol 25 (3) ◽  
pp. 413-422 ◽  
Author(s):  
F. P. V. Maesen ◽  
B. I. Davies ◽  
J. J. A. M. van den Bergh ◽  
H. L. L. Gubbelmans ◽  
J. C. E. Meek ◽  
...  
Keyword(s):  
Prospective Study ◽  
Chronic Bronchitis ◽  
Double Blind ◽  
Acute Exacerbations

Controlled prospective study of oral amoxycillin/clavulanate vs ciprofloxacin in acute exacerbations of chronic bronchitis

1989 ◽  
Vol 24 (suppl B) ◽  
pp. 185-193 ◽  
Author(s):  
E. W. Schmidt ◽  
I. Zimmermann ◽  
W. Ritzerfeld ◽  
E. Voss ◽  
W. T. Ulmer
Keyword(s):  
Prospective Study ◽  
Chronic Bronchitis ◽  
Acute Exacerbations

Relevance of lung ultrasound in the diagnostic algorithm of respiratory diseases in a real‐life setting: A multicentre prospective study

Respirology ◽  
2019 ◽  
Vol 25 (5) ◽  
pp. 535-542 ◽  
Author(s):  
Luca Rinaldi ◽  
Stefania Milione ◽  
Maria Chiara Fascione ◽  
Pia Clara Pafundi ◽  
Concetta Altruda ◽  
...  
Keyword(s):  
Prospective Study ◽  
Respiratory Diseases ◽  
Lung Ultrasound ◽  
Real Life ◽  
Diagnostic Algorithm ◽  
Real Life Setting ◽  
Multicentre Prospective Study

scholarly journals Clinical and Bacteriological Efficacy in Treatment of Acute Exacerbations of Chronic Bronchitis with Cefditoren-Pivoxil versus Cefuroxime-Axetil

2006 ◽  
Vol 50 (5) ◽  
pp. 1762-1767 ◽  
Author(s):  
Jose-Luis Alvarez-Sala ◽  
Peter Kardos ◽  
Jesús Martínez-Beltrán ◽  
Pilar Coronel ◽  
Lorenzo Aguilar
Keyword(s):  
Chronic Bronchitis ◽  
Group Treatment ◽  
Clinical Success ◽  
Cefuroxime Axetil ◽  
Type I ◽  
Clinical Effects ◽  
Double Blind ◽  
Bacteriological Response ◽  
Treatment Difference ◽  
Acute Exacerbations

ABSTRACT A randomized, double-blind, double-dummy trial was performed comparing 200 mg of cefditoren-pivoxil twice daily for 5 days versus standard cefuroxime-axetil treatment (250 mg twice daily for 10 days) of Anthonisen type I or II acute exacerbations of chronic bronchitis. The modified intention-to-treat population included 541 patients. Patients were assessed during therapy, at the end of therapy (visit 3; primary evaluation time point), and at follow-up. Clinical success was obtained in 79.9% of the 264 patients included in the cefditoren-pivoxil group and in 82.7% of the 277 patients in the cefuroxime-axetil group (treatment difference, 95% confidence interval [CI]: −2.8, −9.7 to 3.6%). Treatment clinical effects were more clearly seen in sputum signs (decreasing volume and purulence from approximately 80% to approximately 10% of the patients). At the end of treatment, exploratory analysis of the per-pathogen bacteriological response showed 72.8% (of 103 isolates) in the cefditoren-pivoxil arm versus 67.0% (of 94 isolates) in the cefuroxime-axetil group (treatment difference; 95% CI: 5.8, −7.0 to 18.6%). Globally, the per-pathogen bacteriological response correlated well with clinical success: 83.5% of 164 baseline isolates from patients with a clinical success were eradicated or presumably eradicated, in contrast to only 3% of 33 isolates from patients with a clinical failure. Clinical success in patients infected with Haemophilus influenzae, the most frequent isolate, was 84% (of 50) and 82.5% (of 40) (treatment difference; 95% CI: 1.5, −14 to 17%) in the cefditoren-pivoxil versus the cefuroxime-axetil group. Although this study does not prove that either drug is better than a placebo, cefditoren-pivoxil and the standard 10-day cefuroxime-axetil course had similar point estimates of success in acute exacerbations of chronic bronchitis.

Lead-Free Metal Halide Perovskite Nanocrystals for Photocatalysis in Water

2019 ◽  
Author(s):  
Subhajit Bhattacharjee ◽  
Sonu Pratap Chaudhary ◽  
Sayan Bhattacharyya
Keyword(s):  
Charge Carrier ◽  
Wide Spectrum ◽  
Real Life ◽  
Metal Halide ◽  
Lead Free ◽  
Water Medium ◽  
Type I ◽  
Type Ii ◽  
Perovskite Layer ◽  
Halide Perovskites

<p>Metal halide perovskites with high absorption coefficient, direct generation of free charge carriers, excellent ambipolar charge carrier transport properties, point-defect tolerance, compositional versatility and solution processability are potentially transforming the photovoltaics and optoelectronics industries. However their limited ambient stability, particularly those of iodide perovskites, obscures their use as photocatalysts especially in aqueous medium. In an unprecedented approach we have exploited the photo-absorption property of the less toxic lead-free Cs<sub>3</sub>Bi<sub>2</sub>X<sub>9 </sub>(X = Br, I) nanocrystals (NCs) to catalyse the degradation of water pollutant organic dye, methylene blue (MB) in presence of visible light at room temperature. After providing a proof-of-concept with bromide perovskites in isopropanol, the perovskites are employed as photocatalysts in water medium by designing perovskite/Ag<sub>2</sub>S and perovskite/TiO<sub>2 </sub>composite systems, with Type I (or quasi Type II) and Type II alignments, respectively. Ag<sub>2</sub>S and TiO<sub>2</sub> coatings decelerate penetration of water into the perovskite layer while facilitating charge carrier extraction. With a minimal NC loading, Cs<sub>3</sub>Bi<sub>2</sub>I<sub>9</sub>/Ag<sub>2</sub>S degrades ~90% MB within an hour. Our approach has the potential to unravel the photocatalytic properties of metal halide perovskites for a wide spectrum of real-life applications. </p>

Sign in / Sign up

Export Citation Format

Share Document